NCT04958109View on ClinicalTrials.gov

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Metabolic Diseases
Interventions
DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

Administration of a 75 gm oral glucose tolerance test

DRUG

Kisspeptin

Intravenous administration of kisspeptin 112-121 x 16 hours

DRUG

Placebo

Intravenous administration of Placebo 16 hours

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Massachusetts General Hospital

OTHER

NCT04958109 - Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test | Biotech Hunter | Biotech Hunter